1. Home
  2. TNGX vs AAM Comparison

TNGX vs AAM Comparison

Compare TNGX & AAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • AAM
  • Stock Information
  • Founded
  • TNGX 2014
  • AAM 2024
  • Country
  • TNGX United States
  • AAM United States
  • Employees
  • TNGX N/A
  • AAM N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • AAM
  • Sector
  • TNGX Health Care
  • AAM
  • Exchange
  • TNGX Nasdaq
  • AAM Nasdaq
  • Market Cap
  • TNGX 413.6M
  • AAM 441.9M
  • IPO Year
  • TNGX N/A
  • AAM 2024
  • Fundamental
  • Price
  • TNGX $3.04
  • AAM $10.10
  • Analyst Decision
  • TNGX Strong Buy
  • AAM
  • Analyst Count
  • TNGX 8
  • AAM 0
  • Target Price
  • TNGX $13.14
  • AAM N/A
  • AVG Volume (30 Days)
  • TNGX 1.5M
  • AAM 433.7K
  • Earning Date
  • TNGX 11-06-2024
  • AAM 01-01-0001
  • Dividend Yield
  • TNGX N/A
  • AAM N/A
  • EPS Growth
  • TNGX N/A
  • AAM N/A
  • EPS
  • TNGX N/A
  • AAM N/A
  • Revenue
  • TNGX $43,383,000.00
  • AAM N/A
  • Revenue This Year
  • TNGX $27.73
  • AAM N/A
  • Revenue Next Year
  • TNGX N/A
  • AAM N/A
  • P/E Ratio
  • TNGX N/A
  • AAM N/A
  • Revenue Growth
  • TNGX 15.67
  • AAM N/A
  • 52 Week Low
  • TNGX $2.70
  • AAM $9,600.00
  • 52 Week High
  • TNGX $13.01
  • AAM $15,000.00
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 39.30
  • AAM N/A
  • Support Level
  • TNGX $2.72
  • AAM N/A
  • Resistance Level
  • TNGX $3.29
  • AAM N/A
  • Average True Range (ATR)
  • TNGX 0.30
  • AAM 0.00
  • MACD
  • TNGX 0.07
  • AAM 0.00
  • Stochastic Oscillator
  • TNGX 32.08
  • AAM 0.00

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

About AAM AA Mission Acquisition Corp. Class A Ordinary Shares

AA Mission Acquisition Corp is a blank check company.

Share on Social Networks: